Nikhil Prasad Fact checked by:Thailand Medical News Team Apr 22, 2026 1 hour, 38 minutes ago
Medical News: New Research Reveals Psilocybe cubensis Alters Brain Activity and Neuron Growth
A groundbreaking new preclinical study is drawing serious attention to the therapeutic potential of psychedelic mushrooms, particularly Psilocybe cubensis, in addressing anxiety and depression. By combining behavioral testing with advanced brain monitoring and cellular analysis, researchers have uncovered compelling evidence that both microdosing and macrodosing can significantly influence brain function and emotional regulation.
Ultra-low doses of psychedelic mushrooms may enhance brain plasticity and reduce anxiety and depression
symptoms through measurable neural changes.
Expanding the Search for Better Mental Health Treatments
Depression and anxiety disorders remain among the most widespread mental health conditions globally, often resistant to standard treatments such as selective serotonin reuptake inhibitors. These drugs, while effective for some, can take weeks to produce results and frequently come with side effects that reduce patient compliance.
To address these limitations, researchers from the Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Universidad Nacional Autónoma de México, Universidad Autónoma del Estado de Hidalgo, and Instituto Politécnico Nacional explored the pharmacological effects of whole Psilocybe cubensis mushroom extracts in mice. Unlike many previous studies focusing solely on isolated psilocybin, this research examined the full spectrum of bioactive compounds within the mushroom.
Microdosing Shows Comparable Effects to Antidepressants
The study utilized a carefully designed dosing strategy, including a microdose of just 1 µg/kg administered either acutely or repeatedly over 10 days, alongside a macrodose of 1000 mg/kg. These were compared against fluoxetine at 10 mg/kg.
Behavioral tests revealed that microdosing significantly reduced anxiety-like behaviors. Mice displayed increased time spent in open arms in the elevated plus maze and decreased avoidance behavior, both indicators of reduced anxiety. In the forced swimming test, a standard measure of depressive-like states, microdosed mice exhibited reduced immobility and increased active swimming behavior—effects nearly identical to those seen with fluoxetine treatment.
This
Medical News report highlights that these behavioral improvements were consistent across both acute and repeated dosing, suggesting that even minimal exposure to the mushroom extract can initiate rapid neurobehavioral changes.
Distinct Electrophysiological Signatures in the Brain
Electrocorticographic analysis provided deeper insight into how these effects manifest in the brain. Microdosing produced selective increases in alpha (8–13 Hz) and beta (13–30 Hz) oscillatory activity in the parietal cortex, particularly at 30 and 60 minutes post-administration. These frequency bands are associated with cognitive processing, a
ttention, and emotional regulation.
In contrast, macrodosing led to broader and more intense alterations, including increased power in the 3–6 Hz frequency range and reductions in delta and alpha bands over extended time periods. These findings suggest a dose-dependent modulation of cortical activity, with microdoses fine-tuning neural signaling while macrodoses induce more global changes.
Evidence of Neuroplasticity and Neuronal Maturation
One of the most striking findings of the study was the effect on neuronal structure. Using immunohistochemical analysis of doublecortin-positive cells in the hippocampus, researchers observed significant increases in immature neuron populations following repeated microdosing. These cells are markers of neurogenesis and early neuronal development.
Macrodosing produced even more pronounced changes, including increased dendritic complexity and maturation in multiple neuronal categories within the dentate gyrus. However, these effects appeared transient, with some returning to baseline after seven days.
Such findings point to enhanced neuroplasticity, a critical factor in recovery from depression and chronic stress. The ability to promote new neuron formation and strengthen synaptic connections may underlie the observed behavioral improvements.
Hormonal Regulation and Stress Reduction
The study also measured corticosterone, a stress hormone analogous to cortisol in humans. Repeated microdosing resulted in a statistically significant reduction in corticosterone levels seven days after treatment, indicating a sustained effect on the body’s stress-response system.
Macrodosing also reduced corticosterone levels, but the effect was more immediate and less persistent, again highlighting differences in how dosing strategies influence physiological outcomes.
Complex Mechanisms Beyond Psilocybin Alone
While psilocybin was confirmed as a key component in the mushroom extract through chromatographic analysis, researchers emphasized that other compounds—such as amino acids, sterols, and secondary metabolites—may contribute to the observed effects through synergistic interactions.
This broader biochemical profile may explain why whole mushroom extracts produced robust effects even at extremely low doses, suggesting mechanisms beyond traditional serotonergic pathways, potentially involving noradrenergic and genomic signaling processes.
Conclusion
The study provides compelling evidence that Psilocybe cubensis exerts multifaceted effects on brain function, behavior, and cellular structure. Microdosing, in particular, emerges as a promising strategy capable of delivering rapid and sustained antidepressant and anxiolytic effects without the intensity associated with larger doses. However, these findings are based on animal models, and translation to human clinical use will require rigorous trials to determine safety, efficacy, and optimal dosing regimens. Nonetheless, the data strongly support continued exploration of psychedelic compounds as next-generation therapeutics for mental health disorders, especially in treatment-resistant cases where conventional drugs fall short.
The study findings were published in the peer reviewed journal: Molecules.
https://www.mdpi.com/1420-3049/31/8/1331
For the latest on psilocybin and Psilocybe cubensis mushrooms, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/psychedelic-compounds-could-restore-vision-loss-caused-by-glaucoma
https://www.thailandmedical.news/news/single-dose-psilocybin-quietly-rewires-the-brain
https://www.thailandmedical.news/news/time-for-medical-and-regulatory-agencies-to-embrace-psilocybin-mainstream
https://www.thailandmedical.news/news/psilocybin-emerging-as-a-game-changer-in-mental-health-treatment
https://www.thailandmedical.news/news/psilocin-and-its-role-in-enhancing-brain-plasticity
https://www.thailandmedical.news/news/danish-study-shows-that-regular-low-doses-of-psilocybin-can-help-with-mental-health-disorders
https://www.thailandmedical.news/news/landmark-study-shows-that-single-dose-of-psychedelic-drug-psilocybin-produced-antianxiety-and-antidepressant-effects-that-last-for-years
Medical Disclaimer: All content published by Thailand Medical News is based on scientific research and is intended for informational and educational purposes only. It is not medical advice, diagnosis, or treatment. Readers must not attempt to use, apply, or experiment with any protocols, compounds, or therapies mentioned without first consulting a qualified and licensed medical doctor. Many findings discussed are experimental or preliminary, and only a licensed healthcare professional can determine what is safe and appropriate for an individual’s specific medical condition.
Share
Tweet
Share
